EIGR.Q Stock Overview
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development of therapies for hepatitis delta virus (HDV) and other serious diseases.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Eiger BioPharmaceuticals, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$3.04 |
52 Week High | US$43.35 |
52 Week Low | US$1.10 |
Beta | 1.87 |
1 Month Change | -43.34% |
3 Month Change | -48.30% |
1 Year Change | -89.75% |
3 Year Change | -98.82% |
5 Year Change | -99.05% |
Change since IPO | -99.36% |
Recent News & Updates
Recent updates
Eiger BioPharmaceuticals, Inc.'s (NASDAQ:EIGR) 28% Dip In Price Shows Sentiment Is Matching Revenues
Apr 01The Market Doesn't Like What It Sees From Eiger BioPharmaceuticals, Inc.'s (NASDAQ:EIGR) Revenues Yet As Shares Tumble 26%
Jan 04Analysts Have Just Cut Their Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Revenue Estimates By 22%
Dec 20Analyst Forecasts For Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Are Surging Higher
Nov 09Rock star Growth Puts Eiger BioPharmaceuticals (NASDAQ:EIGR) In A Position To Use Debt
Oct 06Eiger sheds ~20% on abandonment of EUA request for COVID therapy
Oct 05Eiger falls 21% amid uncertainty over regulatory path for COVID-19 therapy
Sep 06Eiger BioPharmaceuticals: Undervalued Biotech With End Of 2022 Catalyst
Jul 26European Commission approves Eiger BioPharmaceuticals' progeria therapy Zokinvy
Jul 20Eiger Biopharmaceuticals: Value Inflection For Lead Asset In HDV Infection On The Horizon
Apr 06Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Analysts Are More Bearish Than They Used To Be
Mar 15Eiger Pharma: HDV Approval In 2023 Is A Major Catalyst
Dec 26Shareholder Returns
EIGR.Q | US Biotechs | US Market | |
---|---|---|---|
7D | 38.8% | 0.4% | 1.0% |
1Y | -89.8% | 0.9% | 21.9% |
Return vs Industry: EIGR.Q underperformed the US Biotechs industry which returned 0.7% over the past year.
Return vs Market: EIGR.Q underperformed the US Market which returned 24.9% over the past year.
Price Volatility
EIGR.Q volatility | |
---|---|
EIGR.Q Average Weekly Movement | 35.3% |
Biotechs Industry Average Movement | 11.6% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.8% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: EIGR.Q's share price has been volatile over the past 3 months.
Volatility Over Time: EIGR.Q's weekly volatility has increased from 24% to 35% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | 25 | David Apelian | www.eigerbio.com |
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development of therapies for hepatitis delta virus (HDV) and other serious diseases. The company offers Zokinvy for the treatment of Hutchinson-Gilford progeria syndrome and Processing-Deficient Progeroid Laminopathies. Its product candidates include Lonafarnib, an orally available, farnesylation inhibitor, which has completed Phase 3 clinical trials for HDV infection; Peginterferon Lambda (lambda), which is in clinical development for HDV; lambda, that is in phase II and III investigator studies of mild and moderate COVID-19; and Avexitide, which is in Phase II for the treatment of congenital hyperinsulinism and post-bariatric hypoglycemia.
Eiger BioPharmaceuticals, Inc. Fundamentals Summary
EIGR.Q fundamental statistics | |
---|---|
Market cap | US$4.50m |
Earnings (TTM) | -US$74.96m |
Revenue (TTM) | US$15.77m |
0.3x
P/S Ratio-0.1x
P/E RatioIs EIGR.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
EIGR.Q income statement (TTM) | |
---|---|
Revenue | US$15.77m |
Cost of Revenue | US$24.00k |
Gross Profit | US$15.75m |
Other Expenses | US$90.71m |
Earnings | -US$74.96m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -50.62 |
Gross Margin | 99.85% |
Net Profit Margin | -475.26% |
Debt/Equity Ratio | -284.4% |
How did EIGR.Q perform over the long term?
See historical performance and comparison